RxDoctor Payments Data

Lindsey Lavin

Family · McDonough, GANPI 1326653296

Payments from drug & device makers

$687in general payments, 2019–2025

Across 45 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$112
  • Otsuka America Pharmaceutical, Inc.$108
  • AstraZeneca$67
  • GSK$65
  • Novo Nordisk$46
  • Kowa Pharmaceuticals America, Inc.$41
  • plus $248 from 13 others

What the payments were for

  • Food & beverage$687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$687 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$69,521
Medicare patients
233
Services billed
2,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$38,294
TrulicityDulaglutide14$23,924
MounjaroTirzepatide20$22,153
JanuviaSitagliptin Phosphate11$17,077
JardianceEmpagliflozin13$15,776
LinzessLinaclotide16$14,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,292
JanumetSitagliptin Phos/Metformin Hcl12$12,222
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,849
Albuterol Sulfate HfaAlbuterol Sulfate64$1,582
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,385
Esomeprazole Magnesium18$1,238
Atorvastatin Calcium168$1,002
Rosuvastatin Calcium79$922
Gabapentin49$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$112$46,07734 claims
Novo NordiskOzempic$46$38,29426 claims
MerckJanuvia, Janumet$12$29,29923 claims
AbbVieLinzess$29$14,78116 claims
GSKTrelegy Ellipta$65$13,29214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →